From Billions to Binders: How Structure-First AI is Reshaping Antibody Discovery

ImmunoAI accelerates antibody discovery by 89% with structure-based AI, heralding a new era in rapid therapeutic development.

Ailurus Press
September 4, 2025
  • Assessment of Therapeutic by Combinations of In Vitro and Methods. (2021). ResearchGate. https://www.researchgate.net/publication/354364344_Assessment_of_Therapeutic_by_Combinations_of_In_Vitro_and_Methods
  • Recent advances in antibody optimization based on deep learning. (2025). PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12119181/
  • AI-driven epitope prediction: a system review, comparative analysis, and practical guide for vaccine development. (2025). npj Vaccines. https://www.nature.com/articles/s41541-025-01258-y
  • About Ailurus

    Ailurus Bio is a pioneering company building biological programs, genetic instructions that act as living software to orchestrate biology. We develop foundational DNAs and libraries, transforming lab-grown cells into living instruments that streamline complex research and production workflows. We empower scientists and developers worldwide with these bioprograms, accelerating discovery and diverse applications. Our mission is to make biology the truly general-purpose technology, as programmable and accessible as modern computers, by constructing a biocomputer architecture for all.

    For more information, visit: ailurus.bio
    Share this post

    Recent posts

    Subscribe and get new posts and updates from Ailurus.

    Subscribe